News

May 18, 2023

Fractyl Health Unveils Groundbreaking Pre-Clinical Proof of Concept Results for its Rejuva® Pancreatic Gene Therapy Platform for Metabolic Diseases at the American Society of Gene & Cell Therapy Congress

...

Read More

May 9, 2023

Fractyl Health to Present Preclinical Proof-of-Concept Data for Rejuva® Pancreatic Gene Therapy Platform Program at the American Society of Gene & Cell Therapy Congress

...

Read More

May 2, 2023

Fractyl Health to Present Scientific Updates on Revita® and Rejuva® Programs at Upcoming Medical Congresses

...

Read More

Apr 24, 2023

Fractyl Health Announces the Initiation of a Global Registry Study of the Revita System™ in Patients With Inadequately Controlled Type 2 Diabetes (T2D)

...

Read More

Feb 7, 2023

Fractyl Health gibt die kommerzielle Verfügbarkeit von Revita in Deutschland und das® erste erfolgreiche Verfahren beim 25. Internationalen Endoskopie-Symposium in Düsseldorf bekannt

...

Read More

Feb 7, 2023

Fractyl Health Announces Commercial Availability of Revita® in Germany and Successful First Procedure at 25th Düsseldorf International Endoscopy Symposium

...

Read More

Jan 31, 2023

Fractyl Health Provides Clinical Update on 24-Week Data from Open Label REVITA-T2Di Cohort

...

Read More

Dec 5, 2022

Fractyl Health Announced Positive Proof-of-Concept Data of Pancreatic GLP-1 Gene Therapy in a Type 2 Diabetes Animal Model at the 20th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

...

Read More

Nov 2, 2022

Fractyl Health Initiates Landmark Scientific Partnership to Study Root Cause Mechanisms Underlying Type 2 Diabetes

...

Read More

May 22, 2022

Fractyl Health Presents New Mechanistic Data on Revita® DMR in Type 2 Diabetes

...

Read More